Clinical Trials on Gastro-enteropancreatic Neuroendocrine Tumor in United States

Total 2501 results

H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

A Phase I/II Study of Dasatinib and Dacarbazine

Metastatic Melanoma

United States
Masonic Cancer Center, University of Minnesota

Suspended

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Relapsed Neuroblastoma | Metastatic Pheochromocytoma

United States
Rockefeller University
Oregon Health and Science University; University of California, Irvine; Skin...

Completed

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Melanoma

United States
Ipsen

Completed

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
M.D. Anderson Cancer Center

Active, not recruiting

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Lung Non-Small Cell Squamous Carcinoma | Stage IIA Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Lung Atypical Carcinoid Tumor | Minimally Invasive Lung Adenocarcinoma | Lung Neuroendocrine Neoplasm | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Skin Cancer | Gastrointestinal Cancer | Neuroendocrine Carcinoma

United States
Yale University

Completed

A Sunscreen Based on Bioadhesive Nanoparticles

Melanoma | UV Ray Skin Damage

United States
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Douglas Tyler
Varian, a Siemens Healthineers Company

Completed

EF5 in Melanoma Patients

Melanoma

United States
California Pacific Medical Center Research Institute
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Melanoma

United States
University of California, San Francisco
Novartis

Completed

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

BRAF Mutant Metastatic Melanoma

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
Darell Bigner
Bristol-Myers Squibb; Duke University; Istari Oncology, Inc.

Withdrawn

PVSRIPO in Combination With Nivolumab in Melanoma (PPD1)

Melanoma

United States
Wolfram Samlowski
Comprehensive Cancer Centers of Nevada

Unknown

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (SART)

Melanoma

United States
Maria Wei

Completed

Patient Preference for Biopsy Notification

Elevated Risk for Melanoma

United States
Georgetown University
Exelixis; Hackensack Meridian Health; MedStar Franklin Square Medical Center

Suspended

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Completed

Molecular Epidemiology of Cutaneous Malignant Melanoma

Melanoma

United States
University of Florida

Completed

Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques

Melanoma

United States
Craig L Slingluff, Jr
GlaxoSmithKline

Completed

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (Mel55)

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Melanoma

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

Melanoma (Skin)

United States
Nektar Therapeutics
ImaginAb, Inc.

Withdrawn

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Metastatic Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
Mt. Sinai Medical Center, Miami
Bayer; Celgene Corporation

Completed

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Malignant Melanoma

United States
Jonsson Comprehensive Cancer Center

Completed

Cytogenetic Study of Ocular Melanoma

Choroidal Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Axitinib + Ipilimumab in Advanced Melanoma

Melanoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer

Melanoma

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Case Comprehensive Cancer Center

Recruiting

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Small-cell Lung Cancer | Large Cell Neuroendocrine Carcinoma of the Lung | Extrapulmonary Small Cell Carcinoma

United States
Lynn E. Spitler, MD
University of California, San Francisco

Completed

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)

Malignant Melanoma, Metastatic

United States
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Georgetown University
Genentech, Inc.; Melanoma Research Alliance

Terminated

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

BRAF-positive Metastatic Melanoma

United States
Novartis Pharmaceuticals

Completed

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Lymphoma | Breast Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Melanoma (Skin) | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma (Skin)

United States
Louisiana State University Health Sciences Center...

Terminated

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
University of Miami

Completed

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
St. Luke's Medical Center

Unknown

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States

Clinical Trials on Gastro-enteropancreatic Neuroendocrine Tumor in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations